Urolithin A and the Longevity Pathways: AMPK, mTOR, and Sirtuins
Key takeaways
- AMPK is the low-fuel alarm, mTOR is the growth signal, and sirtuins are energy-state sensors; together they decide whether a cell grows or repairs.
- Urolithin A's best-established action is triggering mitophagy — the recycling of worn-out mitochondria — first shown in worms and rodents (PRECLINICAL).
- ANIMAL and cell studies link that effect to AMPK activation and reduced mTOR signaling, the same axis exercise and fasting engage.
- Other preclinical work ties urolithin A to the SIRT1–PGC-1α pathway, which governs the building of new mitochondria.
- HUMAN trials confirm downstream effects (muscle mitochondrial markers, strength) but have not directly mapped these signaling pathways in people.
If you read enough longevity science, the same handful of names keep surfacing: AMPK, mTOR, sirtuins. They aren't supplements or diets — they're signaling pathways, the internal switchboard your cells use to decide, moment to moment, whether to grow and store or to conserve and repair. Nearly every intervention with real longevity evidence behind it, from caloric restriction to exercise, works partly by flipping these switches. So a reasonable question for urolithin A is: where does it fit on that switchboard?
The short version is that preclinical research places urolithin A squarely in the "repair" camp — nudging cells toward the same recycling-and-renewal state that fasting and exercise produce. Let's unpack what each pathway does and what the evidence actually supports, keeping a careful line between what's been shown in animals and cells (most of it) and what's been shown in people.
What do AMPK, mTOR, and the sirtuins actually do?
Think of these three as a cellular thermostat for energy and growth.
| Pathway | Senses | When active, it promotes |
|---|---|---|
| AMPK | Low energy (high AMP:ATP ratio) — a "fuel is running low" alarm | Energy production, fat burning, autophagy and mitophagy (cleanup) |
| mTOR | Abundant nutrients and growth signals | Building — protein synthesis, cell growth; it suppresses cleanup |
| Sirtuins (e.g., SIRT1) | Cellular energy state via NAD+ levels | Stress resistance, mitochondrial biogenesis, metabolic efficiency |
AMPK and mTOR are, roughly, opposites. AMPK says "times are lean — conserve, burn stored fuel, and recycle damaged parts." mTOR says "resources are plentiful — grow." Chronic over-activation of mTOR and a sluggish AMPK are features associated with aging tissue; activating AMPK (and periodically dialing down mTOR) is a recurring theme in longevity research. Sirtuins add another layer, tuning mitochondrial biogenesis in response to the cell's NAD+ status. These relationships are laid out in independent reviews of urolithin A's biology (scoping review, 2023).
How does urolithin A engage the AMPK–mTOR axis?
Urolithin A's signature, best-documented action is inducing mitophagy — the targeted recycling of damaged mitochondria. That was first established when researchers showed urolithin A induced mitophagy and extended lifespan in the worm C. elegans and improved muscle function in rodents (Ryu and colleagues, 2016, Nature Medicine; PRECLINICAL) (Ryu et al., 2016).
Mitophagy doesn't happen in a vacuum — it's governed by exactly these nutrient-sensing pathways, and more recent preclinical work has tied urolithin A's effect to the AMPK–mTOR axis directly. In a 2026 animal study of cardiac remodeling, urolithin A was reported to activate mitophagy via the AMPK–mTOR axis — consistent with AMPK activation and reduced mTOR signaling driving the cleanup program (Experimental & Molecular Medicine, 2026; PRECLINICAL). This is the same axis engaged by fasting and endurance exercise, which is why urolithin A is sometimes described as an "exercise mimetic" in the research literature — a label that captures a mechanistic resemblance, not a promise of identical results.
Where do the sirtuins come in?
The sirtuin connection runs through mitochondrial biogenesis — the building of new mitochondria, which complements mitophagy's clearing of old ones. Preclinical studies in middle-aged mice have linked urolithin A to activation of the SIRT1–PGC-1α pathway, with accompanying increases in ATP and NAD+ levels. PGC-1α is the master regulator of mitochondrial biogenesis, so engaging it pairs naturally with urolithin A's cleanup activity: clear out the damaged units, build fresh ones. These mechanistic findings are summarized in a detailed review of urolithin A and muscle aging (Liang et al., 2024, review; the underlying data is PRECLINICAL, and the review's authors are affiliated with the compound's developer).
The picture that emerges from the animal and cell work is a coherent loop: AMPK up, mTOR eased, sirtuin/PGC-1α signaling engaged — a state that favors mitochondrial quality control and renewal over unchecked growth.
Has any of this been confirmed in humans?
This is the crucial caveat. The pathway-level mechanisms above are overwhelmingly PRECLINICAL — worms, mice, and cultured cells. Human trials of urolithin A have measured downstream outcomes rather than mapping the signaling pathways directly. In those trials, supplementation was associated with improved muscle mitochondrial gene expression and reduced plasma acylcarnitines in older adults (Andreux et al., 2019; HUMAN), and with gains in muscle strength plus a higher mitochondrial-to-nuclear DNA ratio and increased mitophagy markers in muscle biopsies (Singh et al., 2022; HUMAN).
Those human results are consistent with the proposed AMPK/mTOR/sirtuin mechanisms — they're the kind of outcomes you'd expect if those pathways were being engaged — but consistency isn't the same as direct confirmation. The honest summary is that the mechanism is well-developed in animals and the downstream human effects are measurable, while the step connecting them in people remains inferred rather than proven.
What does this mean in practice?
You don't need to track your own AMPK to benefit from understanding it. The practical message is that the lifestyle levers with the strongest longevity evidence — regular exercise, not eating constantly, adequate sleep — are the primary ways to keep these pathways tuned toward repair. A compound such as standardized Urolithin A is studied as a complement that may support the mitophagy side of that balance, not a substitute for the behaviors themselves.
For people already committed to those habits and curious about mitochondrial support, a consistent daily dose — for example SOMA Urolithin A gummies — is the kind of steady, long-horizon approach these slow cellular processes reward.
Frequently asked questions
Does urolithin A activate AMPK in humans?
AMPK activation by urolithin A has been shown in animal and cell studies (PRECLINICAL). Human trials show downstream effects consistent with it — such as improved muscle mitochondrial markers — but have not directly measured AMPK activation in people.
Is urolithin A the same as a fasting or exercise mimetic?
It shares some mechanisms with fasting and exercise, particularly engaging the AMPK–mTOR axis and mitophagy, which is why the "mimetic" label appears in research. It is not equivalent to exercise, and it isn't a replacement for physical activity.
Does urolithin A raise NAD+?
Some preclinical studies report increased NAD+ alongside SIRT1–PGC-1α activation in animals. This has not been established as a direct, primary effect in humans, so it's best treated as a preclinical mechanistic observation rather than a proven human outcome.
How is this different from NAD+ boosters like NMN?
NAD+ precursors aim to raise NAD+ to support sirtuin activity; urolithin A works primarily by triggering mitophagy. They act at different points on the same broad longevity switchboard, which is why they're sometimes studied as complementary rather than interchangeable.
Do I need to "cycle" urolithin A to keep these pathways responsive?
The human trials used continuous daily dosing over weeks to months and reported effects on that schedule; they did not test cycling. There's no clinical evidence that cycling is necessary. Consistency over time is what the research protocols actually used.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.